Longest survival follow-up ever reported for immunotherapy treatment in this setting
_256_384.jpg)
This facility manufactures APIs & formulations of oncology and non-oncology products.
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Application based on results from the TROPION-Breast01 Phase III trial
Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Subscribe To Our Newsletter & Stay Updated
